IGF1R protein expression is not associated with differential benefit to concurrent trastuzumab in early-stage HER2+ breast cancer from the North Central Cancer Treatment Group (Alliance) adjuvant trastuzumab trial N9831

Monica M. Reinholz, Beiyun Chen, Amylou C. Dueck, Kathleen Tenner, Karla Ballman, Darren Riehle, Robert B. Jenkins, Xochiquetzal J. Geiger, Ann E. McCullough, Edith A. Perez

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'IGF1R protein expression is not associated with differential benefit to concurrent trastuzumab in early-stage HER2<sup>+</sup> breast cancer from the North Central Cancer Treatment Group (Alliance) adjuvant trastuzumab trial N9831'. Together they form a unique fingerprint.

Medicine & Life Sciences